Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)Chao Zhang, Wen‐Zhao Zhong|Cell Reports Medicine|2024Cited by 31